Markets open

AstraZeneca PLC Ordinary Shares

AZN · NYSE

Symbol: AZN
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: Europe
Exchange: NYSE

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.

Key Issues

Bullish view

A reported $400 billion combination with Bristol Myers Squibb could expand AstraZeneca’s pharmaceutical portfolio and strengthen its competitive position across major therapeutic areas.

Bearish view

The scale of the reported transaction could create substantial execution, financing, regulatory and integration risks, potentially destroying value even if the strategic rationale is sound.

Analyst Consensus

See all

Buy

12 analysts

$161

Current

—

Low

$214

Average

—

High

Average target implies +32.70% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Amgen Inc.AMGN · NASDAQ-GS$403.29

3.40%

Philip Morris International IncPM · NYSE$189.601.44%

Novartis AGNVS · NYSE$154.200.61%

Novo Nordisk A/SNVO · NYSE$44.520.53%

$160.89+$5.273.39%

As of: Aug 5, 7:41 PM

: $155.62
: $249.50B
Open: —
: —
: $164.45 - $160.73
: $212.71 - $153.41
: —
: —
: 6.14M

Notable Price Movement

Aug 3-7$155.628.26%
AstraZeneca fell 9.78% over the week, from $172.48 to $155.62. The decline was concentrated on Monday, when the stock dropped to $157.97 on volume of 16.3 million shares, followed by a further fall to $155.62 on Tuesday. The main reported catalyst was news that AstraZeneca and Bristol Myers Squibb were in talks over a potential $400 billion combination, which appears to have heightened concerns about regulatory scrutiny and integration risks. The stock did not materially reverse the Monday selloff. No company financials were supplied for the period, so the move is best attributed to deal-related uncertainty rather than an earnings update.

Stories & Analysis

AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure

Zacks · 4h ago

Reminder - AstraZeneca (AZN) Goes Ex-Dividend Soon

BNK Invest · 5h ago

MRK Q2 Earnings & Sales Beat Estimates, '26 Sales View Raised

Zacks · 1d ago

Monday's ETF Movers: URA, PPH

BNK Invest · 2d ago

J&J's Strong Q2 Oncology Performance Fuels Future Growth Hopes

Zacks · 2d ago AstraZeneca And Bristol Myers Reportedly In Talks On $400 Bln Deal

RTTNews · 3d ago Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals

RTTNews · 5d ago IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook

Zacks · 6d ago

—

6.00M